2021
30 Rituximab
Gehlhausen J, Heffernan M, Tomayko M. 30 Rituximab. 2021, 330-338.e3. DOI: 10.1016/b978-0-323-61211-1.00030-9.ChaptersMucous membrane pemphigoidEpidermolysis bullosa acquisitaMechanism of actionCutaneous lupusHost diseaseBullous pemphigoidPemphigus vulgarisPemphigus foliaceusRituximabB cellsUS FoodDrug AdministrationDermatologic usesMonoclonal antibodiesPemphigoidTreatmentCD20AcquisitaLupusFoliaceusGraftDiseaseAdministrationAntibodiesPharmacology
2020
Cervical Pemphigus Vulgaris Presenting as Postmenopausal Bleeding
Smith SM, Moscarelli R, Panse G, Parkash V. Cervical Pemphigus Vulgaris Presenting as Postmenopausal Bleeding. International Journal Of Gynecological Pathology 2020, 40: 477-481. PMID: 33323852, DOI: 10.1097/pgp.0000000000000724.Peer-Reviewed Original ResearchConceptsPemphigus vulgarisGenital involvementMucocutaneous blistering diseaseRelapse/recurrenceLong-term survivalCervical involvementPostmenopausal bleedingBullous lesionsCervical originTreatment modalitiesBlistering diseaseUnnecessary interventionsOral cavityPatientsPostmenopausalSymptomsDiseasePemphigusInvolvementVulgarisHysterectomyBleedingCervixPresentingRecurrenceAutoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology
Fichtner ML, Jiang R, Bourke A, Nowak RJ, O’Connor K. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Frontiers In Immunology 2020, 11: 776. PMID: 32547535, PMCID: PMC7274207, DOI: 10.3389/fimmu.2020.00776.Peer-Reviewed Original ResearchConceptsLipoprotein receptor-related protein 4Chronic inflammatory demyelinating polyneuropathyMuSK myasthenia gravisMyasthenia gravisDisease subtypesPathogenic autoantibodiesNeuromyelitis opticaPemphigus vulgarisFab-arm exchangeNeuromuscular junctionAChR myasthenia gravisDistinct immune mechanismsInflammatory demyelinating polyneuropathyAutoimmune myasthenia gravisContribution of complementMuscle-specific kinaseNicotinic acetylcholine receptorsSubtype of diseaseDemyelinating polyneuropathyMG subtypesMG patientsAutoantibody productionClinical benefitAutoimmune diseasesAutoimmune pathology
2015
The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis
Atzmony L, Hodak E, Leshem Y, Rosenbaum O, Gdalevich M, Anhalt G, Mimouni D. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. Journal Of The American Academy Of Dermatology 2015, 73: 264-271. PMID: 26088689, DOI: 10.1016/j.jaad.2015.04.038.Peer-Reviewed Original ResearchConceptsRisk of relapseRandomized Controlled TrialsMeta-analysis of randomized controlled trialsControlled TrialsCumulative glucocorticoid doseOral glucocorticoid treatmentMeta-analysisTreatment of pemphigusSystematic reviewDisease controlGlucocorticoid doseOral glucocorticoidsIntravenous immunoglobulinMycophenolate mofetilPemphigus treatmentAdjuvant therapyPlasma exchangeAdjuvant modalitiesGlucocorticoid treatmentAdverse eventsPemphigus vulgarisPrimary outcomeRelapseSecondary outcomesTen trials
2014
Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Review and Meta-Analysis
Atzmony L, Hodak E, Gdalevich M, Rosenbaum O, Mimouni D. Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Review and Meta-Analysis. American Journal Of Clinical Dermatology 2014, 15: 503-515. PMID: 25403548, DOI: 10.1007/s40257-014-0101-9.Peer-Reviewed Original ResearchConceptsSteroid-sparing effectRemission rateRandomized Controlled TrialsControlled TrialsTreatment modalitiesPemphigus vulgarisTreatment of pemphigus vulgarisTopical epidermal growth factorComplete response ratePemphigus foliaceusCochrane Central Register of Controlled TrialsOptimal therapeutic approachIncreased remission ratesCentral Register of Controlled TrialsMulticenter randomized controlled trialShort-term efficacyRegister of Controlled TrialsCase-control studyMeta-analysesCochrane Central RegisterSteroid-sparingIntravenous immunoglobulinOpen-labelSustained remissionEpidermal growth factorShared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients
Cho MJ, Lo AS, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, Hammers CM, Choi EJ, Sharma PM, Uduman M, Li H, Rux AH, Farber SA, Rubin CB, Kleinstein SH, Sachais BS, Posner MR, Cavacini LA, Payne AS. Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nature Communications 2014, 5: 4167. PMID: 24942562, PMCID: PMC4120239, DOI: 10.1038/ncomms5167.Peer-Reviewed Original ResearchConceptsHumoral immune responsePemphigus vulgarisGene usageImmune responseAnti-Dsg3 antibodiesSomatic mutationsRequirement of mutationsPemphigus vulgaris autoantibodiesBlistering diseasePV patientsVH gene usagePatientsDesmoglein 3Unrelated patientsAutoAbsAutoantibodiesAutoreactivityDsg3MutationsGermline sequencesAbReplacement mutationsVDJ recombinationDiseaseAntibodies
2013
Punctate pemphigus: an underreported direct immunofluorescence pattern
Ko CJ, McNiff JM. Punctate pemphigus: an underreported direct immunofluorescence pattern. Journal Of Cutaneous Pathology 2013, 41: 293-296. PMID: 24372009, DOI: 10.1111/cup.12272.Peer-Reviewed Original ResearchConceptsIntercellular depositionIntercellular IgG depositionDirect immunofluorescence studiesCases of pemphigusDirect immunofluorescence patternsDot-like patternIgG depositionPemphigus vulgarisDiagnostic findingsPemphigus foliaceusPemphigusImmunofluorescence patternImmunoglobulin GImmunofluorescence studiesPotential mechanismsIgGDIF studies
2012
Is it time to re-evaluate the treatment of pemphigus?
Leventhal JS, Sanchez MR. Is it time to re-evaluate the treatment of pemphigus? Journal Of Drugs In Dermatology 2012, 11: 1200-6. PMID: 23134985.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinCorticosteroid-related adverse effectsAdverse effectsTreatment of pemphigusCost of therapySerious adverse effectsManagement of pemphigusBest practice treatmentSystemic corticosteroidsClinical improvementMost patientsMucocutaneous diseaseStandard therapyBiologic agentsImmunosuppressive agentsPemphigus vulgarisBody of evidenceRecent trialsFatal infectionNovel therapiesTherapeutic strategiesPemphigusTherapyRemissionTreatment
2011
Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features
Ko CJ, Milstone LM, Choi J, McNiff JM. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. International Journal Of Dermatology 2011, 50: 1480-1485. PMID: 22097993, DOI: 10.1111/j.1365-4632.2011.04990.x.Peer-Reviewed Original ResearchConceptsCases of PRPPityriasis rubra pilarisCases of erythrodermaCases of psoriasisHistologic featuresClinical contextCorrect clinical settingPresence of acantholysisHailey-Hailey diseaseLichenoid infiltratePapulosquamous lesionsPemphigus vulgarisFocal acantholysisHistologic cluesErythrodermaDarier's diseaseAcantholysisClinical settingDermatology literatureDiseasePsoriasisBiopsyDifferent causesDiagnosisInfiltrates
2009
Absence of human herpesvirus 8 in pemphigus and bullous pemphigoid.
Galan A, Hui P, McNiff JM. Absence of human herpesvirus 8 in pemphigus and bullous pemphigoid. International Journal Of Clinical And Experimental Pathology 2009, 2: 456-62. PMID: 19294004, PMCID: PMC2655157.Peer-Reviewed Original ResearchHuman herpesvirus 8Presence of HHV8Cases of PVBullous pemphigoidPemphigus vulgarisCases of pemphigusHerpesvirus 8Cases of BPAutoimmune vesiculobullous disordersBasement membrane antigensPolymerase chain reaction techniqueAutoimmune attackChain reaction techniqueHHV8 DNAVesiculobullous diseaseVesiculobullous disordersImmunohistochemical expressionVesicobullous disordersSerologic dataImmunohistochemical localizationMembrane antigenPemphigoidNormal skinPemphigusConfirmatory PCR
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply